Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051475 | 0.98 | MMP2 (0.42) | MMP2MMP13MMP1MMP9PIN1 | |
| SCHEMBL4606648 | 0.87 | MMP2 (0.52) | MMP2ALDH1A1GAAMAPK1 | |
| SCHEMBL1422384 | 0.78 | MMP2 (0.48) | MMP2MMP13MMP1MMP9PIN1 | |
| SCHEMBL20206828 | 0.74 | ALDH1A1 (0.33) | ALDH1A1GAA | |
| SCHEMBL4506135 | 0.72 | PIN1 (0.46) | MMP2MMP13MMP1MMP9PIN1 | |
| SCHEMBL20204735 | 0.71 | BRS3 (0.34) | — | |
| SCHEMBL4605593 | 0.70 | MMP2 (0.60) | MMP2ALDH1A1GAAMAPK1 | |
| SCHEMBL14012152 | 0.69 | PIN1 (0.43) | MMP2MMP13MMP1MMP9PIN1 | |
| SCHEMBL20630518 | 0.69 | PIN1 (0.46) | MMP2MMP13MMP1MMP9PIN1 | |
| SCHEMBL12821931 | 0.68 | MMP13 (0.44) | MMP2MMP13MMP1MMP9PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569927-B1 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-7358268-B2 | Imidazole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| EP-1569927-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| WO-2004050636-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | TFPI, F11, TFPI2 | MMP2 220/4885MMP13 603/4885MMP1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.